|Mr. John F. Thero||Chief Exec. Officer, Pres and Director||1.11M||N/A||56|
|Mr. Michael W. Kalb CPA||Chief Financial Officer and Sr. VP||293.2k||N/A||46|
|Dr. Steven B. Ketchum Ph.D.||Chief Scientific Officer, Pres of R&D and Sr. VP||631.56k||N/A||52|
|Mr. Joseph T. Kennedy J.D.||Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec.||672.54k||N/A||49|
|Mr. Frederick W. Ahlholm CPA||Chief Accounting Officer and VP of Fin. & Admin.||N/A||N/A||51|
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companys lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
Amarin Corporation plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.